CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Files Provisional Patent Covering Proprietary Biosynthesis Program

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its filing of a provisional patent application pertaining to the company’s biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature. Per the news release, this patent application, once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions around the world, will offer significant commercial protections for InMed’s promising E. coli-based expression system, which enables the manufacture of any of the 90+ cannabinoid compounds found in the cannabis plant. “This novel approach to the biosynthesis of cannabinoids is a game-changer for drug development,” Dr. Vikramaditya Yadav, Assistant Professor of Chemical and Biological Engineering at the University of British Columbia, stated in the news release. “The importance of producing cannabinoids that are identical to the naturally occurring compounds cannot be overstated. Many drug development efforts with synthetic derivatives have failed.”

To view the full press release, visit http://cnw.fm/Yi0vy

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.

More from CannabisNewsBreaks

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Leave a Reply